Table 3.
Rate of overall survival and progression free survival at 6 months and 12 months.
| Rate, % | TACE-LEN (N=52) | TACE-LEN-C (N=31) |
|---|---|---|
| OS 6 months | 88.2 | 96.7 |
| OS 12 months | 55.1 | 95.7 |
| PFS 6 months | 50 | 93.3 |
| PFS 12 months | 0 | 42.3 |
OS, overall survival; PFS, progression-free survival; TACE-LEN, transcatheter arterial chemoembolization with Lenvatinib; TACE-LEN-C, transcatheter arterial chemoembolization with Lenvatinib plus camrelizumab.